SI20024A - Purinovi L-nukleozidi, analogi in uporaba od teh - Google Patents

Purinovi L-nukleozidi, analogi in uporaba od teh Download PDF

Info

Publication number
SI20024A
SI20024A SI9720067A SI9720067A SI20024A SI 20024 A SI20024 A SI 20024A SI 9720067 A SI9720067 A SI 9720067A SI 9720067 A SI9720067 A SI 9720067A SI 20024 A SI20024 A SI 20024A
Authority
SI
Slovenia
Prior art keywords
group
alkenyl
aralkyl
alkynyl
alkyl
Prior art date
Application number
SI9720067A
Other languages
English (en)
Slovenian (sl)
Inventor
Guangyi Wang
Robert Tam
Deveron Avertt
Original Assignee
Icn Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals, Inc. filed Critical Icn Pharmaceuticals, Inc.
Publication of SI20024A publication Critical patent/SI20024A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SI9720067A 1996-10-16 1997-10-15 Purinovi L-nukleozidi, analogi in uporaba od teh SI20024A (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2858696P 1996-10-16 1996-10-16
US4397497P 1997-04-23 1997-04-23
US5548797P 1997-08-12 1997-08-12
PCT/US1997/018387 WO1998016184A2 (fr) 1996-10-16 1997-10-15 Analogues de nucleosides l purine et leurs utilisations

Publications (1)

Publication Number Publication Date
SI20024A true SI20024A (sl) 2000-02-29

Family

ID=27363301

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720067A SI20024A (sl) 1996-10-16 1997-10-15 Purinovi L-nukleozidi, analogi in uporaba od teh

Country Status (21)

Country Link
US (1) US20020058635A1 (fr)
EP (1) EP0961775B1 (fr)
JP (2) JP2001524936A (fr)
KR (2) KR100412480B1 (fr)
CN (3) CN1233254A (fr)
AT (1) ATE271063T1 (fr)
AU (1) AU727177B2 (fr)
BR (1) BR9714349A (fr)
CA (1) CA2266889A1 (fr)
CZ (1) CZ126799A3 (fr)
DE (1) DE69729887T2 (fr)
HK (1) HK1021738A1 (fr)
HU (1) HUP0001186A3 (fr)
IL (1) IL129118A0 (fr)
NO (3) NO991784L (fr)
PL (1) PL188660B1 (fr)
SI (1) SI20024A (fr)
SK (1) SK48199A3 (fr)
UA (1) UA63984C2 (fr)
WO (1) WO1998016184A2 (fr)
YU (1) YU18899A (fr)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455690B1 (en) * 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
AU743366B2 (en) * 1997-01-17 2002-01-24 Icn Pharmaceuticals, Inc. Novel nucleosides
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP2003511454A (ja) * 1999-08-27 2003-03-25 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド ピロロ［２，３−ｄ］ピリミジンヌクレオシド類似化合物
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
JP2003532643A (ja) 2000-04-13 2003-11-05 フアーマセツト・リミテツド 肝炎ウイルス感染症を治療するための３’−または２’−ヒドロキシメチル置換ヌクレオシド誘導体
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2002014362A2 (fr) 2000-08-17 2002-02-21 Tripep Ab Gene de fusion non structurel ns3/4a du virus de l'hepatite c
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
DK1333833T3 (da) * 2000-10-23 2011-12-12 Glaxosmithkline Llc Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
AP2004003069A0 (en) * 2001-11-27 2004-06-30 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
CA2470521A1 (fr) * 2001-12-21 2003-07-10 Micrologix Biotech Inc. 7-deaza l-nucleosides en tant qu'antiviraux
PT1523489E (pt) * 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
BR0313164A (pt) 2002-08-01 2007-07-17 Pharmasset Inc compostos com o sistema biciclo[4.2.1] nonano para o tratamento de infecções por flaviviridae
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
CN1293884C (zh) * 2002-10-29 2007-01-10 南京长澳医药科技有限公司 6－甲氧基双脱氧鸟苷在制备抗乙肝药物中的应用
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
MXPA05010419A (es) * 2003-03-28 2006-05-31 Pharmasset Inc Compuestos para el tratamiento de infecciones por flaviviridae.
US8044060B2 (en) * 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
WO2004113357A2 (fr) * 2003-05-20 2004-12-29 The Board Of Trustees Of The University Of Illinois Inhibiteurs d'analogues de nucleosides de la transcriptase inverse
WO2005020885A2 (fr) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions et methodes pour le traitement du syndrome respiratoire aigu severe (sras)
PL3521297T3 (pl) * 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
WO2005009418A2 (fr) 2003-07-25 2005-02-03 Idenix (Cayman) Limited Analogues des nucleosides puriques pour traiter flaviviridae et notamment l'hepatite c
WO2005018330A1 (fr) * 2003-08-18 2005-03-03 Pharmasset, Inc. Regime de dosage pour therapie contre flaviviridae
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
CA2576030A1 (fr) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006031725A2 (fr) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation de ribofuranosyle pyrimidines et purines a substitution 2'-fluoro-2'- alkyl- ou eventuellement a autre substitution ainsi que derives de celles-ci
US8133870B2 (en) 2004-10-29 2012-03-13 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
PT1824482E (pt) * 2004-12-17 2014-05-13 Anadys Pharmaceuticals Inc Compostos 3h-oxazolo e 3h-tiazolo[4,5-d]pirimidin-2-ona 3,5- -di-substituídos e 3,5,7-tri-substituídos e seus pró- -fármacos
US7947694B2 (en) 2005-01-14 2011-05-24 Janssen Pharmaceutica Nv Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors
WO2006074985A1 (fr) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrimidines heterocycliques anneles a 5 elements utilises comme inhibiteurs de kinase
PT1891961E (pt) 2005-03-17 2009-12-17 Proyecto Biomedicina Cima Sl Uso de 5'-metiltioadenosina (mta) na prevenção e/ou no tratamento de doenças auto-imunes e/ou rejeição de transplante
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
CA2603163A1 (fr) * 2005-03-25 2006-10-05 Glaxo Group Limited Procede de preparation de derives pyrido[2,3-d]pyrimidin-7-one et 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one
EP1907407A1 (fr) * 2005-07-22 2008-04-09 Giuliani International Limited Ameliorations apportees a des composes analogues de 6-thioguanosine triphosphate, leur utilisation dans les champs medicaux et procedes destines a leur preparation
ITRM20050391A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
CA2630463C (fr) 2005-11-21 2015-01-06 Anadys Pharmaceuticals, Inc. Nouveau procede pour la preparation de 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
JP5345527B2 (ja) * 2006-06-22 2013-11-20 アナディス ファーマシューティカルズ インク プロドラッグである５−アミノ−３−（３’−デオキシ−β−Ｄ−リボフラノシル）−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン
DE602007012881D1 (en) 2006-07-18 2011-04-14 Anadys Pharmaceuticals Inc Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
KR20090057035A (ko) * 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2185195A2 (fr) 2007-08-16 2010-05-19 Tripep Ab Plate-forme immunogène
EP2048151A1 (fr) * 2007-10-10 2009-04-15 Cilag AG Procédé pour la production de nucléosides par glycosylation directe de la base nucléosidique
WO2009068617A1 (fr) 2007-11-30 2009-06-04 Boehringer Ingelheim International Gmbh Dérivés de 1,5-dihydro-pyrazolo(3,4-d)pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a pour le traitement de troubles du snc
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US20100004526A1 (en) 2008-06-04 2010-01-07 Eigen, Inc. Abnormality finding in projection images
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8470834B2 (en) * 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010027935A1 (fr) 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Inhibiteurs d'hydrolase de ahcy pour le traitement de l'hyperhomocystéinémie
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
EP3025727A1 (fr) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Procédés de traitement des maladies du foie
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2376514A2 (fr) 2008-12-23 2011-10-19 Pharmasset, Inc. Analogues de nucléoside
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
ES2460019T3 (es) 2009-03-31 2014-05-13 Boehringer Ingelheim International Gmbh Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de PDE9A
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AR077859A1 (es) 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
US8481711B2 (en) 2010-07-06 2013-07-09 Hidenori Kamanishi Neurite outgrowth agent
HUE033378T2 (en) 2010-08-12 2017-11-28 Boehringer Ingelheim Int 6-Cycloalkyl-1,5-dihydro-pyrazolo [3,4-D] pyrimidin-4-one and their use as PDE9A inhibitors
WO2012040124A1 (fr) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucléosides et analogues nucléotidiques
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2012142075A1 (fr) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales
EP2731433A4 (fr) 2011-07-13 2014-12-31 Merck Sharp & Dohme Analogues de nucléosides 5'-substitués et leurs procédés d'utilisation pour le traitement de maladies virales
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AU2012347785B2 (en) 2011-12-06 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating viral diseases
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2861611B1 (fr) 2012-05-25 2016-07-13 Janssen Sciences Ireland UC Nucléosides dýuracyle spirooxetane
WO2014100505A1 (fr) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Nucléosides, nucléotides substitués et leurs analogues
SI2950786T1 (sl) 2013-01-31 2020-03-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
BR112016012243A2 (pt) * 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de atividade de tnf
WO2015143712A1 (fr) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs nucléosidiques substitués en 4' de la transcriptase inverse
CN104497083B (zh) * 2014-05-12 2017-07-07 河南师范大学 具有抗寄生虫活性的核苷‑苯基丙烯酮杂化体及其制备方法和应用
EP3197457B1 (fr) 2014-09-26 2022-11-09 Riboscience LLC Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial
WO2016091698A1 (fr) 2014-12-08 2016-06-16 F. Hoffmann-La Roche Ag Composés 5-amino-6h-thiazolo [4,5-d]pour le traitement et la prophylaxide d'infections virales
EP3265102A4 (fr) 2015-03-06 2018-12-05 ATEA Pharmaceuticals, Inc. Nucléotides de purine beta-d-2'-désoxy-2'alpha-fluoro-2'-beta-c-substitués-2-modifiés-n6-substitués pour le traitement du virus de l'hépatite c
PT3270915T (pt) 2015-03-16 2020-06-17 H Hoffnabb La Roche Ag Tratamento combinado com um agonista do tlr7 e um inibidor da montagem da cápside do vhb
WO2016180691A1 (fr) 2015-05-08 2016-11-17 F. Hoffmann-La Roche Ag Nouveaux acides carboxyliques oxathiolane et dérivés pour le traitement et la prophylaxie d'une infection virale
EP3294746B1 (fr) 2015-05-12 2021-10-06 F. Hoffmann-La Roche AG Dérivés d'aminothiazolopyrimidine dione substitués pour le traitement et la prophylaxie d'une infection virale
CN104844673B (zh) * 2015-06-04 2017-09-08 新乡学院 一种制备天然核苷水粉蕈素的方法
JP6839104B2 (ja) 2015-06-30 2021-03-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン
MX2018003212A (es) 2015-09-23 2018-07-06 Merck Sharp & Dohme Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
JP7005508B2 (ja) 2016-03-24 2022-01-21 ノバルティス アーゲー ヒトライノウイルスの阻害剤としてのアルキニルヌクレオシド類似体
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
JP7201598B2 (ja) 2017-01-06 2023-01-10 エフ．ホフマン－ラ ロシュ アーゲー ３位置換５－アミノ－６Ｈ－チアゾロ［４，５－ｄ］ピリミジン－２，７－ジオン化合物の製造法
CN108329372B (zh) * 2017-01-20 2022-07-26 浙江省亚热带作物研究所 N6-(2-羟乙基)腺苷及其衍生物在制备治疗痛风药物中的应用
SG10202012214WA (en) 2017-02-01 2021-01-28 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
BR112020023866A2 (pt) 2018-05-25 2021-04-06 Primmune Therapeutics, Inc. Agonistas de tlr7
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물
CN111973615A (zh) * 2019-05-22 2020-11-24 华东理工大学 一种治疗躁狂型精神障碍及精神分裂症的药物
KR20220150879A (ko) 2019-11-26 2022-11-11 프리뮨 테라퓨틱스, 인크. Tlr7 효능제
CN118598916A (zh) 2020-02-18 2024-09-06 吉利德科学公司 抗病毒化合物
TW202245800A (zh) 2020-02-18 2022-12-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
JP2023533724A (ja) 2020-07-02 2023-08-04 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物
WO2022046989A1 (fr) 2020-08-27 2022-03-03 Incyte Corporation Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2
WO2022140231A1 (fr) 2020-12-21 2022-06-30 Incyte Corporation Composés de déazaguanine utilisés en tant qu'inhibiteurs de v617f de jak2
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (fr) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Composes phospholipidiques et leurs procedes de production et d'utilisation
WO2023178285A1 (fr) 2022-03-17 2023-09-21 Incyte Corporation Composés d'urée tricycliques en tant qu'inhibiteurs de jak2 v617f

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166141A (en) * 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
IL85778A0 (en) * 1987-03-20 1988-09-30 Bristol Myers Co Production of 2',3'-dideoxynucleosides and certain such novel compounds
US5041426A (en) * 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
AU4134793A (en) * 1992-06-22 1993-12-23 Eli Lilly And Company 2'-deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
FI932943A (fi) * 1993-06-24 1994-12-25 Irri Oy Automaattinen työkalunvaihto
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5672594A (en) * 1994-10-24 1997-09-30 Genencor International, Inc. L-erythrosyl nucleosides
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
WO1998005817A1 (fr) * 1996-08-07 1998-02-12 Henkel Corporation Auxiliaire non solvant de colorant polyester
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof

Also Published As

Publication number Publication date
CN1286258A (zh) 2001-03-07
HK1021738A1 (en) 2000-06-30
KR100386140B1 (ko) 2003-06-02
JP2002105096A (ja) 2002-04-10
CA2266889A1 (fr) 1998-04-23
NO20004328D0 (no) 2000-08-31
NO991784L (no) 1999-06-15
EP0961775A2 (fr) 1999-12-08
NO991784D0 (no) 1999-04-15
DE69729887D1 (de) 2004-08-19
CN1296011A (zh) 2001-05-23
HUP0001186A3 (en) 2002-04-29
AU4899997A (en) 1998-05-11
CN1233254A (zh) 1999-10-27
KR100412480B1 (ko) 2003-12-31
YU18899A (sh) 2002-09-19
NO20004328L (no) 1999-06-15
NO20004326L (no) 1999-06-15
BR9714349A (pt) 2000-11-14
PL332694A1 (en) 1999-09-27
AU727177B2 (en) 2000-12-07
IL129118A0 (en) 2000-02-17
ATE271063T1 (de) 2004-07-15
WO1998016184A3 (fr) 1998-05-28
SK48199A3 (en) 2000-01-18
DE69729887T2 (de) 2005-07-28
EP0961775B1 (fr) 2004-07-14
US20020058635A1 (en) 2002-05-16
CZ126799A3 (cs) 1999-07-14
UA63984C2 (uk) 2004-02-16
KR20000049181A (ko) 2000-07-25
NO317259B1 (no) 2004-09-27
NO316895B1 (no) 2004-06-14
NO20004326D0 (no) 2000-08-31
EP0961775A4 (fr) 2001-09-12
JP2001524936A (ja) 2001-12-04
WO1998016184A2 (fr) 1998-04-23
PL188660B1 (pl) 2005-03-31
HUP0001186A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
SI20024A (sl) Purinovi L-nukleozidi, analogi in uporaba od teh
US6479463B1 (en) Purine L-nucleosides, analogs and uses thereof
EP1027359B9 (fr) L nucleosides monocycliques, analogues et leurs utilisations
RU2259831C2 (ru) Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием
EP1132393B1 (fr) L-Ribavirine et son utilisation
EP1072607A2 (fr) Analogues de nucléosides-L-purine et leurs utilisations
RU2183639C2 (ru) Пуриновые l-нуклеозиды, их аналоги и применение
AU751742B2 (en) Purine L-nucleosides, analogs and uses thereof
HRP20000422A2 (en) Purine l-nucleosides, analogs and uses thereof
NZ505554A (en) 8-substituted alpha or beta L guanosine analogs and derivatives useful for modulating Th1 and Th2 activities in a patient
HRP990148A2 (en) Purine l-nucleosides, analogs and uses thereof
HRP20000420A2 (en) Purine l-nucleosides, analogs and uses thereof
NZ505553A (en) 8-substituted alpha or beta L-guanosine analogs and uses thereof
CA2323791A1 (fr) Analogues de nucleosides l purine et leurs utilisations